November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib shows promise in improving frontal fibrosing alopecia symptoms.
2 citations
,
November 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral tofacitinib can treat both psoriasis and alopecia universalis by normalizing inflammatory pathways.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
21 citations
,
September 2019 in “Journal of the American Academy of Dermatology” Ixekizumab effectively treats generalized pustular psoriasis.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
6 citations
,
March 2023 in “Journal of Ethnopharmacology” Jieduquyuziyin prescription helps treat SLE with atherosclerosis by improving cholesterol removal and reducing inflammation.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
107 citations
,
December 2003 in “Dermatologic Therapy” Interferon, especially alfa interferon, is an effective treatment for cutaneous T-cell lymphoma with manageable side effects.
1 citations
,
October 2024 in “Journal of the Endocrine Society” Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
January 2022 in “Drugs of Today” January 2021 in “Research Portal Denmark” Tofacitinib helped a man with alopecia totalis regrow all his hair.
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
7 citations
,
September 2006 in “Clinical lymphoma & myeloma” Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.
June 2020 in “Jurnal Penyakit Dalam Indonesia” Anti-DFS70 antibodies can help identify nonsystemic autoimmune conditions in SLE patients.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
April 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
40 citations
,
July 2015 in “Kidney International” IL-3 worsens lupus nephritis and blocking it improves kidney health.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.